Profile: Halozyme Therapeutics Inc (HALO.O)
Halozyme Therapeutics, Inc., incorporated on August 23, 2007, is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix. The Company’s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.
Hylenex Recombinant (hyaluronidase human injection)
Hylenex recombinant is a formulation of rHuPH20 that has received the United States Food and Drug Administration (FDA) approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography and to improve resorption of radiopaque agents. The Company is assessing its commercial and strategic options for the product to address additional uses, such as in connection with insulin pumps.
More Physiologic (Ultrafast) Insulin Program
The Company’s program uses rHuPH20 with prandial (mealtime or rapid-acting) insulin for the treatment of diabetes mellitus. The Company is combining rHuPH20 with a rapid acting analog insulin, such as insulin lispro (Humalog) (Lispro-PH20), insulin aspart (Novolog) (Aspart-PH20) and insulin glulisine (Apidra), (each such combination, Analog-PH20), to accelerate their action. The Company is to pre-administer Hylenex recombinant in analog insulin pump therapy at the time of infusion site change (once every 48-72 hours).
The Company developed an an investigational PEGylated form of rHuPH20 (PEGPH20), a new molecular entity, as a candidate for the systemic treatment of tumors that accumulate HA. The Company is conducting clinical trials with PEGPH20 in the treatment of solid tumors. In these trials, a dose of oral dexamethasone, a steroid, is administered to all patients prior to and subsequent to intravenous administration of PEGPH20 to minimize the side effect of PEGPH20. The Company has identified its intended Phase II dose of PEGPH20 in combination with gemcitabine, a chemotherapeutic drug.
HTI-501, an engineered drug formulation variant of cathepsin L (a lysosomal proteinase), that acts by degrading collagen. Collagen is an abundant protein in the body, particularly in connective tissue, and is present in high amounts in the extracellular matrix in the form of collagen fibers. The Company is exploring HTI-501 as an approach to the treatment of edematous fibrosclerotic panniculopathy, also known as cellulite.
The Company competes with Bausch & Lomb Inc.
Halozyme Therapeutics Inc
11388 Sorrento Valley Road
SAN DIEGO CA 92121